Literature DB >> 10969261

A trial of oats in children with newly diagnosed celiac disease.

E J Hoffenberg1, J Haas, A Drescher, R Barnhurst, I Osberg, F Bao, G Eisenbarth.   

Abstract

OBJECTIVE: To determine whether consumption of oats is safe in children with newly diagnosed celiac disease who are starting a gluten-free diet. STUDY
DESIGN: We conducted a self-controlled, open-label, 6-month trial of a commercial oat breakfast cereal product. Primary outcome variables were small bowel histomorphology and anti-tissue transglutaminase IgA antibody titer.
RESULTS: The 10 children who completed the study were 6.8 +/- 4.0 (mean +/- SD) years of age and 5 were male. Over 6.6 +/- 0.7 months, they consumed 24 grams of oat cereal per day, or 1.2 +/- 0.9 g/kg/d. Compared with start of study, at completion there was a significant decrease in biopsy score (P <.01), intra-epithelial lymphocyte count (P <.005), anti-tissue transglutaminase IgA antibody titer (P <.01), and number of symptoms (P <.01).
CONCLUSIONS: We conclude that consumption of a commercially available oat cereal product for 6 months is safe for children with celiac disease beginning a gluten-free diet. Studies are needed to determine the long-term safety of including oat cereal in the gluten-free diet.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10969261     DOI: 10.1067/mpd.2000.109003

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  22 in total

1.  Immunohistochemical analysis of coeliac mucosa following ingestion of oats.

Authors:  U Srinivasan; E Jones; J Carolan; C Feighery
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

2.  A novel and sensitive method for the detection of T cell stimulatory epitopes of alpha/beta- and gamma-gliadin.

Authors:  E H A Spaenij-Dekking; E M C Kooy-Winkelaar; W F Nieuwenhuizen; J W Drijfhout; F Koning
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

Review 3.  Recent advances in coeliac disease.

Authors:  D A van Heel; J West
Journal:  Gut       Date:  2006-07       Impact factor: 23.059

Review 4.  Recent advances in the understanding of celiac disease: therapeutic implications for the management of pediatric patients.

Authors:  John H Kwon; Richard J Farrell
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

5.  Celiac disease--hidden and dangerous.

Authors:  Shelley Case; Paul C Adams
Journal:  Can J Gastroenterol       Date:  2006-09       Impact factor: 3.522

Review 6.  (Outcome) Measure for (Intervention) Measures: A Guide to Choosing the Appropriate Noninvasive Clinical Outcome Measure for Intervention Studies in Celiac Disease.

Authors:  Prashant Singh; Jocelyn A Silvester; Daniel Leffler
Journal:  Gastroenterol Clin North Am       Date:  2018-12-13       Impact factor: 3.806

7.  Immunological indicators of coeliac disease activity are not altered by long-term oats challenge.

Authors:  S E J Cooper; N P Kennedy; B M Mohamed; M Abuzakouk; J Dunne; G Byrne; G McDonald; A Davies; C Edwards; J Kelly; C F Feighery
Journal:  Clin Exp Immunol       Date:  2013-03       Impact factor: 4.330

8.  Avenin fails to induce a Th1 response in coeliac tissue following in vitro culture.

Authors:  C Kilmartin; S Lynch; M Abuzakouk; H Wieser; C Feighery
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

Review 9.  Coeliac disease and oats: a systematic review.

Authors:  N Y Haboubi; S Taylor; S Jones
Journal:  Postgrad Med J       Date:  2006-10       Impact factor: 2.401

10.  Oats to children with newly diagnosed coeliac disease: a randomised double blind study.

Authors:  L Högberg; P Laurin; K Fälth-Magnusson; C Grant; E Grodzinsky; G Jansson; H Ascher; L Browaldh; J-A Hammersjö; E Lindberg; U Myrdal; L Stenhammar
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.